For example, gemticabine-Chk1 inhibitor treatment is an effective treatment for p21/p53 double mutant bladder cancer; nevertheless, cancer cells lose their sensitivity to the combined therapy once p21 is restored, pointing out the importance of considering p21-p53 balance in therapeutic approaches [152]. This evidence concerns the gene CDKN1A and cancer.